查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1673492

双特异性抗体市场：全球市场机会、剂量、专利、定价、销售、临床试验趋势（2030年）

Global Bispecific Antibody Market Opportunity, Drug Dosage, Patent, Price, Sales & Clinical Trials Insight 2030
出版日期: | 出版商: KuicK Research | 英文 1000 Pages | 商品交期: 最快1-2个工作天内

价格

在持续创新和病患接受度不断提高的推动下，双特异性抗体已成为医药市场上最有前景和商业上最成功的标靶方法之一。这一惊人成长的关键驱动因素是双特异性抗体临床试验数量的急剧增加，将从2015年的不到 100个增加到2025年的650 多个。这项进步将为药物开发商、临床研究组织、医生和患者等多方利害关係人带来重大利益。截至2025年 3月，已有 17 种双特异性抗体在主要市场获得批准，累计销售额超过 350亿美元，而2015年首个双特异性抗体获得批准时销售额为 7,700万美元。

双特异性抗体市场预计在2024年达到约 120亿美元，到2030年将呈指数成长至 500亿美元。该成长轨迹显示对能够满足未满足的医疗需求的创新生物製剂的需求不断增加。值得注意的是，Hemlibra 和 Vabysmo 已成为全球双特异性抗体市场的主要参与者，合计占总销售额的75%以上。Roche开发的双特异性抗体Hemlibra用于治疗血友病A，同样由Roche开发的Bavismo用于治疗黄斑部病变和黄斑水肿。预计到2024年，这两种药物的销售额将超过 40亿美元，成为各自治疗领域的主要进入者，并巩固Roche在双特异性抗体市场的领导地位。

目前还有几种双特异性抗体审查核准。值得注意的是，美国 FDA 和欧洲药品管理局（EMA）审查一种开发双特异性抗体 Linvoseltamab，用于治疗多发性骨髓瘤。另一个有希望的候选药物Odronextamab目前接受 FDA 审查，用于治疗多种血液系统恶性肿瘤。这些发展凸显了双特异性抗体研究的进展及其彻底改变癌症治疗的潜力。

截至2025年 3月，已有 600 多种双特异性抗体临床试验中，证明了该类治疗在多个治疗领域的巨大潜力。美国在研发和销售方面继续成为双特异性抗体的最大市场，反映了其在医药创新和医疗保健支出方面的领导地位。

本报告研究了全球双特异性抗体市场，并概述了市场以及药物趋势、临床试验趋势、区域趋势以及参与市场的公司的竞争格局。

目录

第1章 双特异性抗体简介

第2章 双特异性抗体组合策略

  • 化疗
  • 标靶治疗
  • 免疫疗法
  • 放射治疗

第3章 已上市双特异性抗体洞察

第4章 独特的双特异性抗体平台

第5章 全球与区域双特异性抗体市场展望

  • 年度与季销售洞察（2020-2024年）
  • 已核准的双特异性抗体的偿付政策
  • 2030年全球双特异性抗体市场预测

第6章 全球双特异性抗体市场趋势：依地区

  • 日本
  • 韩国
  • 美国
  • 欧洲
  • 中国
  • 英国
  • 澳洲
  • 加拿大
  • 拉丁美洲

第7章 全球双特异性抗体研究与市场趋势：依适应症

  • 淋巴瘤
  • 多发性骨髓瘤
  • 白血病
  • 肺癌
  • 恶性黑色素瘤
  • 消化系统癌症
  • 其他癌症
  • 血液疾病
  • 自体免疫疾病与发炎性疾病
  • 微生物疾病
  • 眼部疾病

第8章 Blincyto – 临床、专利、定价与销售见解

第9章 Hemlibra – 临床、专利、定价与销售见解

第10章 Rybrevant – 临床、专利和定价见解

第11章 Vabysmo – 临床、专利、定价与销售洞察

第12章 Lunsumio – 临床、专利、定价与销售见解

第13章 Kaitani - 临床与商业见解

第14章 Tecvayli – 临床、专利和定价见解

第15章 Columvi – 临床、专利、定价与销售洞察

第16章 Epkinly – 临床、专利、定价与销售见解

第17章 Talvey – 临床、专利和定价见解

第18章 Elrexfio – 临床、专利和定价见解

第19章 Imdelltra – 临床、专利、定价与销售见解

第20章 Ivonescimab – 临床见解

第21章 Ordspono – 临床与销售见解

第22章 Ziihera – 临床、定价与销售见解

第23章 Bizengri – 临床、专利、定价与销售见解

第24章 Korjuny - 临床见解

第25章 全球双特异性抗体临床试验（依公司、适应症和阶段）

  • 调查
  • 临床前
  • 第一阶段
  • 第一/第二阶段
  • 第二阶段
  • 第二/第三阶段
  • 第三阶段
  • 预先报名
  • 已註册

第26章 依公司、国家和适应症对已上市双特异性抗体的临床见解

第27章 竞争格局

  • ABL Bio
  • Abzyme Therapeutics
  • Affimed Therapeutics
  • Akeso Biopharma
  • Alligator Bioscience
  • Amgen
  • Antibody Therapeutics
  • APITBIO
  • Aptevo Therapeutics
  • Astellas Pharma
  • AstraZeneca
  • BioAtla
  • Biosion
  • Biotheus
  • BJ Bioscience
  • EpimAb Biotherapeutics
  • FutureGen Biopharmaceutical
  • Genentech
  • Genmab
  • Gensun Biopharma
  • Harbour BioMed
  • IGM Biosciences
  • I-MAB Biopharma
  • ImmuneOnco Biopharma
  • Innovent Biologics
  • Invenra
  • Janssen Research & Development
  • Kenjockety Biotechnology
  • LaNova Medicines Limited
  • Light Chain Bioscience
  • Linton Pharm
  • Lyvgen Biopharma
  • MacroGenics
  • Merus
  • NovaRock Biotherapeutics
  • Pfizer
  • Phanes Therapeutics
  • Prestige BioPharma
  • Regeneron Pharmaceuticals
  • Revitope
  • Roche
  • Virtuoso Therapeutics
  • Xencor
  • Y-Biologics
  • Zhejiang Shimai Pharmaceutical
  • Zymeworks

Global Bispecific Antibody Market Opportunity, Drug Dosage, Patent, Price, Sales & Clinical Trials Insight 2030 Report findings & Highlights:

  • Global & Regional Market Size, Clinical Trends Insight
  • Global Bispecific Antibodies Sales Opportunity US$ 50 Billion By 2030
  • Global Bispecific Antibodies Sales Surpassed US$ 11 Billion In 2024
  • 17 Bispecific Antibodies Approved Across Key Markets
  • Approved Antibodies Dosage, Patent, Pricing & Sales Insight
  • Comprehensive Insight On More than 600 Bispecific Antibodies In Clinical Trials
  • Global Bispecific Antibodies Clinical Trials By Company, Indication & Phase

Bispecific antibodies have emerged as one of the most promising and commercially successful targeting approaches in the pharmaceutical market, driven by continuous innovations and growing patient acceptance. A major factor contributing to this phenomenal growth is the exponential increase in the number of clinical trials for bispecific antibodies, which has surpassed 650 in 2025 from less than 100 in 2015. This progress has significantly benefited multiple stakeholders like drug developers, clinical research organizations, physicians, and patients. As of March 2025, 17 bispecific antibodies have been approved across key markets, with cumulative sales exceeding US$ 35 Billion as compared to US$ 77 Million in 2015 when the first bispecific antibody was approved.

The bispecific antibody market reached approximately US$ 12 billion in 2024, with projections by Kuick Research suggesting that this market will surge to US$ 50 billion by 2030. This growth trajectory highlights the increasing demand for innovative biologics that can address unmet medical needs. Notably, Hemlibra and Vabysmo have emerged as major contributors to the global bispecific antibodies market, collectively accounting for over 75% of the total sales. Hemlibra, a bispecific antibody developed by Roche, is used to treat hemophilia A, while Vabysmo, also developed by Roche, is a treatment for macular degeneration and macular edema. Both drugs saw sales surpassing US$ 4 Billion in 2024, emerging as key players in their respective therapeutic areas and solidifying Roche's leadership in the market for bispecific antibodies.

There are also several bispecific antibodies currently under regulatory review. Notably, Linvoseltamab, an investigational bispecific antibody, is undergoing review by the US FDA and the European Medicines Agency (EMA) for the treatment of multiple myeloma. Another promising candidate, Odronextamab, is currently under FDA review for the treatment of various hematologic malignancies. These developments underscore the ongoing progress in bispecific antibody research and their potential to revolutionize cancer treatment.

As of March 2025, more than 600 bispecific antibodies are currently undergoing clinical trials, demonstrating the immense potential of these therapeutics across multiple therapeutic areas. The US remains the largest market for bispecific antibodies in terms of both research and development (R&D) and sales, reflecting the country's leadership in pharmaceutical innovation and healthcare spending.

Leading players in the bispecific antibody market include Roche, Gilead, Amgen, Pfizer, Johnson & Johnson (Janssen), and others. These companies are at the forefront of developing innovative bispecific therapies, with a focus on oncology and other high-need areas. For example, Roche has leveraged its expertise in biologics to bring to market Hemlibra and Vabysmo, while Amgen is advancing bispecific T-cell engagers for cancer immunotherapy.

In addition to these leading companies, there have been significant regulatory designations granted to bispecific antibodies, enhancing the overall market landscape. Ivonescimab, a PD-1 x VEGF bispecific antibody developed by Akeso, received FDA Fast Track Designation in October 2024 for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations in the second-line or beyond setting. This designation accelerates the development process and highlights the growing interest in bispecific antibodies for treating cancer. Akeso is collaborating with Summit Therapeutics in the US and other countries to develop Ivonescimab.

Additionally, Invenra's Novel Antibody INV724 has received both Rare Pediatric Disease and Orphan Drug Designations from the US FDA for the treatment of neuroblastoma, a rare and aggressive cancer affecting children. INV724 targets the GD2 and B7-H3 antigens and has shown promise in early-stage clinical trials, offering hope for more effective treatments for pediatric cancers.

In conclusion, the bispecific antibody market is poised for substantial growth, driven by increasing approvals, ongoing clinical trials, and strong regulatory support. With major players like Roche, Gilead, Amgen, and Pfizer leading the charge, and promising candidates undergoing review, bispecific antibodies are set to transform the landscape of modern therapeutics. The market's rapid expansion from US$ 12 Billion in 2024 to an expected US$ 50 Billion by 2030, reflects the increasing recognition of bispecific antibodies as key solutions for treating complex and life-threatening diseases.

Table of Contents

Table of Contents

1. Introduction To Bispecific Antibody

  • 1.1 Overview
  • 1.2 Clinical Advancement of Bispecific Antibodies

2. Bispecific Antibodies Combination Strategies

  • 2.1 Chemotherapy
  • 2.2 Targeted Therapy
  • 2.3 Immunotherapies
  • 2.4 Radiotherapy

3. Commercially Approved Bispecific Antibodies Insight

  • 3.1 Company, Indication, Location & MOA
  • 3.2 Bispecific Antibodies Granted FDA & EMA Designations

4. Bispecific Antibodies Proprietary Platforms

5. Global & Regional Bispecific Antibody Market Outlook

  • 5.1 Yearly & Quarterly Sales Insight (2020 to 2024)
  • 5.2 Approved Bispecific Antibodies Reimbursement Policy
  • 5.3 Global Bispecific Antibody Market Forecast 2030

6. Global Bispecific Antibody Market Trends By Region

  • 6.1 Japan
  • 6.2 South Korea
  • 6.3 US
  • 6.4 Europe
  • 6.5 China
  • 6.6 UK
  • 6.7 Australia
  • 6.8 Canada
  • 6.9 Latin America

7. Global Bispecific Antibodies Research & Market Trends By Indications

  • 7.1 Lymphoma
  • 7.2 Multiple Myeloma
  • 7.3 Leukemia
  • 7.4 Lung Cancer
  • 7.5 Melanoma
  • 7.6 Gastrointestinal Cancers
  • 7.7 Other Cancers
  • 7.8 Blood Disorders
  • 7.9 Autoimmune & Inflammatory Diseases
  • 7.10 Microbial Diseases
  • 7.11 Ocular Diseases

8. Blincyto - Clinical, Patent, Pricing & Sales Insight

  • 8.1 Overview & Patent Insight
  • 8.2 Pricing & Dosage Analysis
  • 8.3 Sales Analysis

9. Hemlibra - Clinical, Patent, Pricing & Sales Insight

  • 9.1 Overview
  • 9.2 Pricing & Dosage Insight
  • 9.3 Sales Analysis

10. Rybrevant - Clinical, Patent & Pricing Insight

  • 10.1 Overview
  • 10.2 Pricing & Dosage Insight

11. Vabysmo - Clinical, Patent, Pricing & Sales Insight

  • 11.1 Overview
  • 11.2 Pricing & Dosage Insight
  • 11.3 Sales Analysis

12. Lunsumio - Clinical, Patent, Pricing & Sales Insight

  • 12.1 Overview & Patent Insight
  • 12.2 Pricing & Dosage Insight
  • 12.3 Sales Analysis

13. Kaitani - Clinical & Sales Insight

14. Tecvayli - Clinical, Patent & Pricing Insight

  • 14.1 Overview & Patent Insight
  • 14.2 Pricing & Dosage Insight
  • 14.3 Sales Analysis

15. Columvi - Clinical, Patent, Pricing & Sales Insight

  • 15.1 Overview & Patent Insight
  • 15.2 Pricing & Dosage Insight
  • 15.3 Sales Analysis

16. Epkinly - Clinical, Patent, Pricing & Sales Insight

  • 16.1 Overview
  • 16.2 Pricing & Dosage Insight
  • 16.3 Sales Analysis

17. Talvey - Clinical, Patent & Pricing Insight

  • 17.1 Overview & Patent Insight
  • 17.2 Pricing & Dosage Insight

18. Elrexfio - Clinical, Patent & Pricing Insight

  • 18.1 Overview
  • 18.2 Pricing & Dosage Insight
  • 18.3 Sales Analysis

19. Imdelltra - Clinical, Patent, Pricing & Sales Insight

  • 19.1 Overview & Patent Insight
  • 19.2 Pricing & Dosage Insight
  • 19.3 Sales Analysis

20. Ivonescimab - Clinical Insight

21. Ordspono - Clinical & Sales Insight

  • 21.1 Overview
  • 21.2 Sales Analysis

22. Ziihera - Clinical, Pricing & Sales Insight

  • 22.1 Overview
  • 22.2 Pricing & Dosage
  • 22.3 Sales Insight

23. Bizengri - Clinical, Patent, Pricing & Sales Insight

  • 23.1 Overview
  • 23.2 Dosing & Pricing

24. Korjuny - Clinical Insight

25. Global Bispecific Antibodies Clinical Trials By Company, Indication & Phase

  • 25.1 Research
  • 25.2 Preclinical
  • 25.3 Phase-I
  • 25.4 Phase-I/II
  • 25.5 Phase-II
  • 25.6 Phase-II/III
  • 25.7 Phase-III
  • 25.8 Preregistration
  • 25.9 Registered

26. Marketed Bispecific Antibodies Clinical Insight By Company, Country & Indication

27. Competitive Landscape

  • 27.1 ABL Bio
  • 27.2 Abzyme Therapeutics
  • 27.3 Affimed Therapeutics
  • 27.4 Akeso Biopharma
  • 27.5 Alligator Bioscience
  • 27.6 Amgen
  • 27.7 Antibody Therapeutics
  • 27.8 APITBIO
  • 27.9 Aptevo Therapeutics
  • 27.10 Astellas Pharma
  • 27.11 AstraZeneca
  • 27.12 BioAtla
  • 27.13 Biosion
  • 27.14 Biotheus
  • 27.15 BJ Bioscience
  • 27.16 EpimAb Biotherapeutics
  • 27.17 FutureGen Biopharmaceutical
  • 27.18 Genentech
  • 27.19 Genmab
  • 27.20 Gensun Biopharma
  • 27.21 Harbour BioMed
  • 27.22 IGM Biosciences
  • 27.23 I-MAB Biopharma
  • 27.24 ImmuneOnco Biopharma
  • 27.25 Innovent Biologics
  • 27.26 Invenra
  • 27.27 Janssen Research & Development
  • 27.28 Kenjockety Biotechnology
  • 27.29 LaNova Medicines Limited
  • 27.30 Light Chain Bioscience
  • 27.31 Linton Pharm
  • 27.32 Lyvgen Biopharma
  • 27.33 MacroGenics
  • 27.34 Merus
  • 27.35 NovaRock Biotherapeutics
  • 27.36 Pfizer
  • 27.37 Phanes Therapeutics
  • 27.38 Prestige BioPharma
  • 27.39 Regeneron Pharmaceuticals
  • 27.40 Revitope
  • 27.41 Roche
  • 27.42 Virtuoso Therapeutics
  • 27.43 Xencor
  • 27.44 Y-Biologics
  • 27.45 Zhejiang Shimai Pharmaceutical
  • 27.46 Zymeworks

List of Figures

List of Figures

  • Figure 1-1: Bispecific Antibodies - Advantages
  • Figure 2-1: Antibody-Chemotherapy Combination - Advantages
  • Figure 2-2: Antibody-Chemotherapy Combination - Impending Challenges
  • Figure 3-1: Blincyto - Mechanism of Action
  • Figure 3-2: Hemlibra - Mechanism of Action
  • Figure 3-3: Rybrevant - Mechanism of Action
  • Figure 3-4: Regulatory Designations - Benefits
  • Figure 4-1: Multiclonics - Distinctive Characteristics
  • Figure 4-2: Biclonics - Format
  • Figure 4-3: ADAPTIR Bispecific Structure
  • Figure 4-4: ADAPTIR-FLEX
  • Figure 4-5: BEAT Platform - Multispecific Antibodies
  • Figure 4-6: FIT-Ig - Proprietary Bispecific Platform
  • Figure 4-7: BiClone format
  • Figure 4-8: BioAtla CABs - Features
  • Figure 4-9: BioAtla CABs - Benefits
  • Figure 4-10: IMBiologic Bispecific Antibodies - Strategy
  • Figure 4-11: IMBiologic Bispecific Antibodies - Mechanism of Action
  • Figure 4-12: Novel HBICE
  • Figure 4-13: HBICE - Mechanism of Action 1
  • Figure 4-14: HBICE - Mechanism of Action 2
  • Figure 4-15: Phanes Therapeutics - PACbody Platform
  • Figure 4-16: Phanes Therapeutics - SPECpair Platform
  • Figure 4-17: Phanes Therapeutics - ATACCbody
  • Figure 4-18: Numab Therapeutics - Technology
  • Figure 4-19: Grabody I Platform - Mechanism of Action
  • Figure 4-20: Grabody I Platform - Mechanism of Action
  • Figure 4-21: 3-Step DuoBody Production Process
  • Figure 4-22: DuoHexaBody Molecules - Schematic
  • Figure 4-23: iTAb - Patented Structure
  • Figure 4-24: iTAb - Mechanism of Action
  • Figure 4-25: Synimmune - Proprietary Bispecific Antibody Format
  • Figure 4-26: BiTE - Structure
  • Figure 4-27: BiTE Molecule
  • Figure 4-28: Sanyou Super Trillion Common Light Chain Antibody Discovery Platform
  • Figure 4-29: ALiCE - Characteristics
  • Figure 4-30: ALiCE - Schematic Diagram & Mechanism of Action
  • Figure 4-31: Abz2 Bispecific Platform
  • Figure 4-32: Abz2 Bispecifics - Benefits
  • Figure 4-33: Neo-X-Prime Bispecific Mechanism
  • Figure 4-34: B-Body Bispecific Antibody - Structre
  • Figure 4-35: xLinkBsAb - Structure
  • Figure 4-36: PrecisionGATE Bispecific Antibody - Structure
  • Figure 5-1: Global - Annual Bispecific Antibody Market (US$ Million), 2020-2024
  • Figure 5-2: Global - Annual Bispecific Antibodies Market By Drugs (US$ Million), 2024
  • Figure 5-3: Global - Bispecific Antibodies Market Shares by Drugs (%), 2024
  • Figure 5-4: Global - Quarterly Bispecific Antibody Market (US$ Million), 2024
  • Figure 5-5: Global - Annual Bispecific Antibody Market By Region (US$ Million), 2024
  • Figure 5-6: Global - Bispecific Antibody Market Shares By Region (%), 2024
  • Figure 5-7: US -Bispecific Antibody Market (US$ Million), 2020-2024
  • Figure 5-8: US - Quarterly Bispecific Antibodies Market (US$ Million), 2024
  • Figure 5-9: US - Quarterly Bispecific Antibodies Market (US$ Million),2023
  • Figure 5-10: ROW -Bispecific Antibody Market Value (US$ Million), 2020-2024
  • Figure 5-11: ROW - Quarterly Bispecific Antibodies Market (US$ Million), 2024
  • Figure 5-12: ROW - Quarterly Bispecific Antibodies Market (US$ Million), 2023
  • Figure 5-13: Global - Bispecific Antibodies Market By Drug (US$ Million), 2023
  • Figure 5-14: Global - Bispecific Antibodies Market Shares By Drugs (%), 2023
  • Figure 5-15: Global - Quarterly Bispecific Antibody Market (US$ Million), 2023
  • Figure 5-16: Global - Bispecific Antibody Market By Region (US$ Million), 2023
  • Figure 5-17: Global - Bispecific Antibody Market Shares By Region (%), 2023
  • Figure 5-18: Blincyto - Total Treatment Cost & Reimbursement Cost
  • Figure 5-19: Blincyto - In Pocket & Out of Pocket Cost of Treatment
  • Figure 5-20: Hemlibra - Total Treatment Cost & Reimbursement Cost
  • Figure 5-21: Hemlibra - In Pocket & Out Of Pocket Cost Of Treatment
  • Figure 5-22: Rybrevant - Maximum Coverage By Medicaid (US$), 2023
  • Figure 5-23: Rybrevant - Maximum Coverage By Private Insurance Coverage (US$), 2021
  • Figure 5-24: Vabysmo - Total Treatment Cost & Reimbursement Cost
  • Figure 5-25: Vabysmo - In Pocket & Out Of Pocket Cost Of Treatment
  • Figure 5-26: Global - Bispecific Antibody Market Opportunity Assessment (US$ Billion), 2025 - 2030
  • Figure 6-1: US - Bispecific Antibodies Approval
  • Figure 7-1: Bispecific Antibodies - Advantages
  • Figure 7-2: HX009-II-02 Phase 1/2 Study - Initiation & Completion Year
  • Figure 7-3: Bispecific Antibodies - Future Opportunities in Melanoma
  • Figure 7-4: Mim8 Phase 3 (NCT05878938) Study - Initiation & Completion Year
  • Figure 7-5: NXT007 Phase 1/2 (NCT05987449) Study - Initiation & Completion Year
  • Figure 7-6: HMB-001 Phase 1/2 (NCT06211634) Study - Initiation & Completion Year
  • Figure 8-1: Blincyto - Approval Year By Region
  • Figure 8-2: Blincyto - Patent Filing & Expiration Year
  • Figure 8-3: Blincyto - Treatment Regimen Cycles (Weeks)
  • Figure 8-4: Blincyto - Duration Of Treatment Phase & Resting Phase In Induction & Consolidation Cycles For Treatment Of MRD-Positive B-Cell Precursor (Days)
  • Figure 8-5: Blincyto - Recommended Number Of Induction & Consolidation Treatment Cycle For Relapsed B-Cell Precursor ALL
  • Figure 8-6: Blincyto - Duration Of Single Induction, Consolidation, Continued Cycle & Full Treatment For Relapsed B-Cell Precursor ALL (Weeks)
  • Figure 8-7: Global - Blincyto Sales (US$ Million), 2020-2024
  • Figure 8-8: Global - Blincyto Sales Quaterly (US$ Million), 2024
  • Figure 8-9: Global - Blincyto Sales Quaterly (US$ Million), 2023
  • Figure 8-10: Blincyto - Sales By Region (US$ Million), 2024
  • Figure 8-11: Blincyto - Sales By Region (%), 2024
  • Figure 8-12: Blincyto - Sales By Region (US$ Million), 2023
  • Figure 8-13: Global - Blincyto Sales By Region (%), 2023
  • Figure 8-14: US - Blincyto Sales ((US$ Million), 2020-2024
  • Figure 8-15: US - Blincyto Sales Quaterly (US$ Million), 2024
  • Figure 8-16: US - Blincyto Sales Quaterly (US$ Million), 2023
  • Figure 8-17: ROW - Blincyto Sales (US$ Million), 2020-2024
  • Figure 8-18: ROW - Blincyto Sales Quaterly (US$ Million), 2024
  • Figure 8-19: ROW - Blincyto Sales Quaterly (US$ Million), 2023
  • Figure 9-1: Hemlibra - Approval Years By Region
  • Figure 9-2: Hemlibra - Cost per Unit & Supply of 30 mg/mL Subcutaneous Injection Of Different Volumes (US$), March'2025
  • Figure 9-3: Hemlibra - Cost per Unit & Supply of 150 mg/mL Subcutaneous Injection Of Different Volumes (US$), March'2025
  • Figure 9-4: Hemlibra - Recommended Loading & Maintenance Dose For Treatment Of Hemophilia (mg/kg/Week)
  • Figure 9-5: Global - Hemlibra Sales (US$ Million), 2020-2024
  • Figure 9-6: Global - Hemlibra Sales Quaterly (US$ Million), 2024
  • Figure 9-7: Global - Hemlibra Sales Quaterly (US$ Million), 2023
  • Figure 9-8: US - Hemlibra Sales (US$ Million), 2020-2024
  • Figure 9-9: US - Hemlibra Sales Quaterly (US$ Million), 2024
  • Figure 9-10: US - Hemlibra Sales Quaterly (US$ Million), 2023
  • Figure 9-11: Europe - Hemlibra Sales (US$ Million), 2020-2024
  • Figure 9-12: Europe - Hemlibra Sales Quaterly (US$ Million), 2024
  • Figure 9-13: Europe - Hemlibra Sales Quaterly (US$ Million), 2023
  • Figure 9-14: Japan - Hemlibra Sales (US$ Million), 2020-2024
  • Figure 9-15: Japan - Hemlibra Sales Quaterly (US$ Million), 2024
  • Figure 9-16: Japan - Hemlibra Sales Quaterly (US$ Million), 2023
  • Figure 9-17: ROW - Hemlibra Sales (US$ Million), 2020-2024
  • Figure 9-18: ROW - Hemlibra Sales Quaterly (US$ Million), 2024
  • Figure 9-19: ROW - Hemlibra Sales Quaterly (US$ Million), 2023
  • Figure 9-20: Global - US v/s ex-US Sales (US$ Million), 2024
  • Figure 9-21: Global - Hemlibra Annual Sales By Region (US$ Million), 2024
  • Figure 9-22: Global - Hemlibra Sales By Region (%), 2024
  • Figure 9-23: Global - US v/s Ex-US Sales (US$ Million), 2023
  • Figure 9-24: Global - Hemlibra Annual Sales By Region (US$ Million), 2023
  • Figure 9-25: Global - Hemlibra Sales By Region (%), 2023
  • Figure 10-1: Rybrevant - Patent Filing & Expiration Year
  • Figure 10-2: Rybrevant - Price Per Unit & Supply Of Intravenous Solution (US$), March'2025
  • Figure 10-3: Rybrevant - Recommended Dose Per Cycle By Body Weight (mg)
  • Figure 10-4: Rybrevant - Dose Reduction In Patients With Weight Less Than 80 kg (mg)
  • Figure 10-5: Rybrevant - Dose Reduction in Patients with Weight more than 80 Kg (mg)
  • Figure 11-1: Vabysmo - Approval Year By Region
  • Figure 11-2: Rybrevant - Patent Filing & Expiration Year
  • Figure 11-3: Vabysmo - Price Per Unit & Supply Of Intravitreal Solution (US$), March'2025
  • Figure 11-4: Global - Vabysmo Sales (US$ Million), 2022-2024
  • Figure 11-5: Global - Vabysmo Sales Quaterly (US$ Million), 2024
  • Figure 11-6: Global - Vabysmo Sales Quaterly (US$ Million), 2023
  • Figure 11-7: US - Vabysmo Sales (US$ Million), 2022-2024
  • Figure 11-8: US - Vabysmo Sales Quaterly (US$ Million), 2024
  • Figure 11-9: US - Vabysmo Sales Quaterly (US$ Million), 2023
  • Figure 11-10: Europe - Vabysmo Sales (US$ Million), 2022-2024
  • Figure 11-11: Europe - Vabysmo Sales Quaterly (US$ Million), 2024
  • Figure 11-12: Europe - Vabysmo Sales Quaterly (US$ Million), 2023
  • Figure 11-13: Japan - Vabysmo Sales (US$ Million), 2022-2024
  • Figure 11-14: Japan - Vabysmo Sales Quaterly (US$ Million), 2024
  • Figure 11-15: Japan - Vabysmo Sales Quaterly (US$ Million), 2023
  • Figure 11-16: ROW - Vabysmo Sales (US$ Million), 2022-2024
  • Figure 11-17: ROW - Vabysmo Sales Quaterly (US$ Million), 2024
  • Figure 11-18: ROW - Vabysmo Sales Quaterly (US$ Million), 2023
  • Figure 11-19: Global - Vabysmo US v/s Ex-US Sales (US$ Million), 2024
  • Figure 11-20: Global - Vabysmo Annual Sales by Region (US$ Million), 2024
  • Figure 11-21: Global - Vabysmo Sales By Region (%), 2024
  • Figure 11-22: Global - Vabysmo US v/s Ex-US Sales (US$ Million), 2023
  • Figure 11-23: Global - Vabysmo Annual Sales By Region (US$ Million), 2023
  • Figure 11-24: Global - Vabysmo Sales By Region (%), 2023
  • Figure 12-1: Lunsumio - Approval Years By Region
  • Figure 12-2: US - Price Per Unit & Supply of Lunsumio Intravenous Solution (US$), March'2025
  • Figure 12-3: EU - Price Per Unit & Supply of Lunsumio Intravenous Solution (US$), March'2025
  • Figure 12-4: Global - Lunsumio Sales (US$ Million), 2022-2024
  • Figure 12-5: Global - Lunsumio Sales Quaterly (US$ Million), 2024
  • Figure 12-6: Global - Lunsumio Sales Quaterly (US$ Million), 2023
  • Figure 12-7: US - Lunsumio Sales (US$ Million), 2022-2024
  • Figure 12-8: US - Lunsumio Sales Quaterly (US$ Million), 2024
  • Figure 12-9: US - Lunsumio Sales Quaterly (US$ Million), 2023
  • Figure 12-10: Europe - Lunsumio Sales (US$ Million), 2022-2024
  • Figure 12-11: Europe - Lunsumio Sales Quaterly (US$ Million), 2024
  • Figure 12-12: Europe - Lunsumio Sales Quaterly (US$ Million), 2023
  • Figure 12-13: ROW - Lunsumio Sales (US$ Million), 2022-2024
  • Figure 12-14: ROW - Lunsumio Sales Quaterly (US$ Million), 2024
  • Figure 12-15: Lunsumio - US v/s Ex-US Sales (US$ Million), 2024
  • Figure 12-16: Global - Lunsumio Annual Sales By Region (US$ Million), 2024
  • Figure 12-17: Global - Lunsumio Sales By Region (%), 2024
  • Figure 12-18: Global - US v/s Ex-US Sales (US$ Million), 2023
  • Figure 12-19: Global - Lunsumio Annual Sales By Region (US$ Million), 2023
  • Figure 12 20: Global - Lunsumio Sales By Region (%), 2023
  • Figure 13-1: China - Kaitani Sales (US$ Million), 2022-2023
  • Figure 13-2: China - Kaitani Sales (US$ Million), H1-H2'2023
  • Figure 14-1: Tecvayli - Approval Years by Region
  • Figure 14-2: Tecvayli - Patent Acceptance & Expiration Year
  • Figure 14-3: US - Cost Per Unit & Supply Of Tecvayli Subcutaneous Solution (US$), March'2025
  • Figure 14-4: EU - Cost of Supply Of Tecvayli Subcutaneous Solution (US$), March'2025
  • Figure 14-5: Global - Tecvayli Sales (US$ Million), 2022-2024
  • Figure 14-6: Global - Tecvayli Sales Quaterly (US$ Million), 2024
  • Figure 14-7: Global - Tecvayli Sales Quaterly (US$ Million), 2023
  • Figure 14-8: US - Tecvayli Sales (US$ Million), 2022-2024
  • Figure 14-9: US - Tecvayli Sales Quaterly (US$ Million), 2024
  • Figure 14-10: US - Tecvayli Sales Quaterly (US$ Million), 2023
  • Figure 14-11: ROW - Tecvayli Sales (US$ Million), 2022-2024
  • Figure 14-12: ROW - Tecvayli Sales Quaterly (US$ Million), 2024
  • Figure 14-13: ROW - Tecvayli Sales Quaterly (US$ Million), 2023
  • Figure 14-14: Tecvayli - US v/s Ex-US Sales (US$ Million), 2024
  • Figure 14-15: Tecvayli - US v/s Ex-US Sales (%), 2024
  • Figure 14-16: Tecvayli - US v/s Ex-US Sales (US$ Million), 2023
  • Figure 14-17: Tecvayli - US v/s Ex-US Sales (%), 2023
  • Figure 15-1: Columvi - Approval Year By Region
  • Figure 15-2: US - Price Per Unit & Supply Of Columvi Intravenous Solution (US$), March'2025
  • Figure 15-3: EU - Price Of Supply Of Columvi Intravenous Solution (US$), March'2025
  • Figure 15-4: Global - Columvi Sales (US$ Million), 2023-2024
  • Figure 15-5: Global - Columvi Sales Quaterly (US$ Million), 2024
  • Figure 15-6: Global - Columvi Sales Quaterly (US$ Million), 2023
  • Figure 15-7: US - Columvi Sales (US$ Million), 2023-2024
  • Figure 15-8: US - Columvi Sales Quaterly (US$ Million), 2024
  • Figure 15-9: US - Columvi Sales Quaterly (US$ Million), 2023
  • Figure 15-10: Europe - Columvi Sales (US$ Million), 2023 & 2024
  • Figure 15-11: Europe - Columvi Sales Quaterly (US$ Million), 2024
  • Figure 15-12: Europe - Columvi Sales Quaterly (US$ Million), 2023
  • Figure 15-13: ROW - Columvi Sales (US$ Million), 2023 & 2024
  • Figure 15-14: ROW - Columvi Sales Quaterly (US$ Million), 2024
  • Figure 15-15: ROW - Columvi Sales Quaterly (US$ Million), 2023
  • Figure 15-16: Global - Columvi US v/s Ex-US Sales (US$ Million), 2024
  • Figure 15-17: Global - Columvi Annual Sales By Region (US$ Million), 2024
  • Figure 15-18: Global - Columvi Sales By Region (%), 2024
  • Figure 15-19: Global - Columvi US v/s Ex-US Sales (US$ Million), 2023
  • Figure 15-20: Global - Columvi Annual Sales By Region (US$ Million), 2023
  • Figure 15-21: Global - Columvi Sales By Region (%), 2023
  • Figure 16-1: Epkinly - Approval Year By Region
  • Figure 16-2: US - Cost Per Unit & Supply Of Epkinly Subcutaneous Solution (US$), March'2025
  • Figure 16-3: EU - Cost Of Supply Of Epkinly Subcutaneous Solution (US$), March'2025
  • Figure 16-4: Global - Epkinly Sales (US$ Million), 2023 & 2024
  • Figure 16-5: Global - Epkinly Sales Reported By Genmab (US$ Million), 2023 & 2024
  • Figure 16-6: Global - Epkinly Sales Reported By AbbVie (US$ Million), 2023 & 2024
  • Figure 16-7: Global - Epkinly Sales By Company (US$ Million), 2024
  • Figure 16-8: Global - Epkinly Sales By Company (US$ Million), 2023
  • Figure 17-1: Talvey - Approval Year By Region
  • Figure 17-2: Talquetamab - FDA & EMA Designation Year
  • Figure 17-3: Talvey - Patent Acceptance & Expiration Year
  • Figure 17-4: US - Price Per Unit & Supply Of Talvey Intravenous Solution (US$), March'2025
  • Figure 17-5: EU - Price Per Supply Of Talvey Intravenous Solution (US$), March'2025
  • Figure 18-1: Elrexfio - Approval Year by Region
  • Figure 18-2: Elranatamab - FDA & EMA Designation Year
  • Figure 18-3: US - Price Per Unit & Supply Of Elrexfio Subcutaneous Solution (US$), March'2025
  • Figure 18-4: Global - Elrexfio Sales (US$ Million), 2023 & 2024
  • Figure 18-5: US - Elrexfio Sales (US$ Million), 2023 & 2024
  • Figure 18-6: ROW - Elrexfio Sales (US$ Million), 2023 & 2024
  • Figure 19-1: Imdelltra - Approval Year By Region
  • Figure 19-2: US - Price Of Supply Of Imdelltra Intravenous Powder (US$), March'2025
  • Figure 19-3: EU - Price Of Supply Of Imdelltra Intravenous Powder (US$), March'2025
  • Figure 19-4: Global - Imdelltra Sales (US$ Million), 2024
  • Figure 19-5: Global - Imdelltra Sales Quaterly (US$ Million), 2024
  • Figure 21-1: Global - Ordspono Sales (US$ Million), 2022-2024
  • Figure 21-2: Global - Ordspono Sales Quaterly (US$ Million), 2024
  • Figure 22-1: US - Price Per Unit & Supply Of Ziihera (US$), March'2025
  • Figure 22-2: Global - Ziihera Sales (US$ Million), 2024
  • Figure 23-1: Zenocutuzumab - Active Patents

List of Tables

  • Table 2-1: Bispecific Antibody & Chemotherapy Combinations in Clinical Trials
  • Table 2-2: Bispecific Antibody & Targeted Therapy Combinations in Clinical Trials
  • Table 2-3: Bispecific Antibody & Immunotherapy Combinations in Clinical Trials
  • Table 2-4: Bispecific Antibody & Radiotherapy Combinations in Clinical Trials
  • Table 3-1: Approved Bispecific Antibodies
  • Table 3-2: US - Bispecific Antibodies with Regulatory Designations
  • Table 3-3: EU - Bispecific Antibodies with Regulatory Designations
  • Table 3-4: China - Bispecific Antibodies with Regulatory Designations
  • Table 5-1: Epkinly - Billing Unit Application For Doses
  • Table 5-2: Talvey - Coverage Summary
  • Table 5-3: Talvey - Coding Summary
  • Table 5-4: Elrexfio - HCPCS Codes
  • Table 5-5: Elrexfio - HCPCS Modifiers
  • Table 5-6: Imdelltra - Payer Coverage & Reimbursement Details
  • Table 5-7: Ziihera - ICD-10-CM Codes
  • Table 5-8: Ziihera - ICD-10-PCS Codes
  • Table 6-1: US - Some FDA Designated Bispecific Antibodies
  • Table 6-2: US - Bispecific Antibodies With Recent IND Clearances
  • Table 6-3: EU - Bispecific Antibodies in Late Stage Clinical Trials
  • Table 6-4: Latin America - Bispecific Antibodies in Clinical Trials
  • Table 7-1: Lymphoma - Bispecific Antibodies in Clinical Trials
  • Table 7-2: Multiple Myeloma - Bispecific Antibodies in Clinical Trials
  • Table 7-3: Leukemia - Bispecific Antibodies in Clinical Trials
  • Table 7-4: Lung Cancer - Bispecific Antibodies in Clinical Trials
  • Table 7-5: Melanoma - Bispecific Antibodies in Clinical Trials
  • Table 7-6: Gastrointestinal Cancers - Bispecific Antibodies in Clinical Trials
  • Table 8-1: Blincyto - Active Patents
  • Table 8-2: Blincyto - Recommended Dosage & Schedule For The Treatment of MRD-Positive B-Cell Precursor ALL
  • Table 8-3: Blincyto - Recommended Dosage & Schedule for Treatment Of Relapsed Or Refractory B-Cell Precursor ALL
  • Table 8-4: Blincyto - Recommended Dosage & Schedule For Treatment Of Relapsed Or Refractory B-Cell Precursor ALL
  • Table 10-1: Rybrevant - Premedication
  • Table 10-2: Rybrevant - Dose Reductions For Adverse Reactions
  • Table 10-3: Rybrevant - Recommended Dosage Modifications For Adverse Reactions
  • Table 12-1: Lunsumio - Recommended Treatment Cycles
  • Table 12-2: Lunsumio - Recommended Premedications
  • Table 12-3: Lunsumio - Recommendations For Management Of Cytokine Release Syndrome
  • Table 14-1: Tecvayli - Dosing Schedule
  • Table 14-2: Tecvayli - Recommended Dosage Modifications For Adverse Reactions
  • Table 15-1: Columvi - Dosing Schedule (21-Day Treatment Cycles)
  • Table 15-2: Columvi - Premedications To Be Administered
  • Table 15-3: Columvi - Recommendations For Management Of Cytokine Release Syndrome
  • Table 15-4: Columvi - Recommended Dosage Modification For Neurologic Toxicity (Including ICANS)
  • Table 15-5: Columvi - Recommended Dosage Modifications For Other Adverse Reactions
  • Table 16-1: Epkinly - Dosage Schedule
  • Table 16-2: Epkinly - Recommendations For Management Of Cytokine Release Syndrome
  • Table 16-3: Epkinly - Recommendations for Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
  • Table 16-4: Epkinly - Recommended Dosage Modifications For Other Adverse Reactions
  • Table 17-1: Talvey - Weekly Dosing Schedule
  • Table 17-2: Talvey - Biweekly Dosing Schedule
  • Table 17-3: Talvey - Recommendations for Management of CRS
  • Table 17-4: Talvey - Recommendations for Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
  • Table 17-5: Talvey - Recommendations For Management Of Neurologic Toxicity (excluding ICANS)
  • Table 17-6: Talvey - Recommended Dosage Modifications For Other Adverse Reactions
  • Table 18-1: Elrexfio - Dosing Schedule
  • Table 18-2: Elrexfio - Recommendations For Management Of CRS
  • Table 18-3: Elrexfio - Recommended Dosage Modifications For Other Adverse Reactions
  • Table 22-1: Ziihera - Dosage Modifications For Adverse Reactions
  • Table 23-1: Bizengri - Premedications Prior To Infusions
  • Table 23-2: Bizengri - Recommended Dosage Modifications & Management For Adverse Reactions